Pioneering Study Aims to Inspire Further Research into Food Sensitivity Testing

Stone Diagnostics' State-of-the-Art Preventive Diagnostic Testing Platforms Empower ACE Providers to Optimize Patient Outcomes With Preventative Diagnostic Testing Solutions

Biotech leader named President and CEO of the Madison Medical group of businesses

Senzo Health Limited (London, UK) ("Senzo"), a life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, this week announced an additional $1.8m investment for its breakthrough Amplified Lateral Flow (ALF) test technology, advancing its mission to bring high-quality, affordable tests into the home.

Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities.

dIFine 30 system is ZEUS Scientific's complete solution for IFA slide processing and digital immunofluorescence imaging

In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies

The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo's Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples

Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo's Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

OBDeleven launches its BMW application that allows easy-to-use customization and diagnostic features for daily drivers of the BMW Group vehicles.

The ISO 13485:2016 certification confirms Senzo as a leading provider of in vitro diagnostic device development, as it brings its Amplified Lateral Flow (ALF) technology to market

After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

Funds will be used to bring the Amplified Lateral Flow (ALF) COVID-19 at-home rapid test through regulatory approval and to market, increase manufacturing capabilities, and advance the development of a range of new tests to significantly improve the diagnosis of the world's most prevalent and deadly diseases

After two years of complete redesign, Tribun Health is proud to announce the release of TeleSlide Patho 5.

World's first amplified lateral flow rapid test combines the accuracy and early detection of central lab testing with the simplicity, speed, and low cost of traditional lateral flow tests

The Florida-based, globally respected cardiologist brings decades of leadership experience to the newly formed board.

The companies have signed a memorandum of understanding to connect patients and clinicians to Boditech's biomarker products.

The South Korean in-vitro diagnostics company sells more than 90 biomarker products, including capillary blood, venous blood, and plasma testing, in 120 countries. To start its expansion, Boditech will open a Miami, Florida, manufacturing site employing hundreds of Americans.

After a year of unprecedented growth, healthcare tech company plans to add 20+ new employees across sales and operations

Webinar on the latest developments in the analysis of single-cell data, including from transcriptomic and imaging technologies.

Lipid inCode® offers greater diagnostic information for hypercholesterolemia sufferers over current NHS standard

Commencement of regulatory pathway for U.S. market approval

First closing of Series A round and onboarding of top biotech leaders to fuel growth in 2022

Inanovate hires new CEO to help drive next phase of growth and bring novel new blood testing technology for cancer into the clinic.

Ellie and PSIvet join forces to enhance the diagnostic experience for over 5,500 veterinary clinics nationwide

Major precision medicine market players include Eli Lilly & Company, bioMérieux, Laboratory Corporation Of America Holdings, Pfizer, Qiagen, Medtronic, Novartis, Quest Diagnostics, Abbott, Roche, Cancer Genetics, Glaxosmithkline Plc (GSK), AstraZeneca, Bristol-Myers Squibb, Thermo Fisher Scientific, Myriad Genetics, Foundation Medicine and Cepheid.

Groundbreaking Diagnostic Platform Provides Faster, Cheaper COVID Test Results in Less Than Two Minutes, Detecting Variants and Very Low Viral Thresholds

The Porex Life Sciences Institute Launches Saletto™ Oral Fluid Collection Device

Among One of the Fastest-Growing Urgent Care Clinics in Texas, NLUC Has Now Earned the Highest Level of Distinction in Patient Care